{"id":24714,"date":"2025-11-28T11:31:06","date_gmt":"2025-11-28T11:31:06","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=24714"},"modified":"2025-11-28T12:46:26","modified_gmt":"2025-11-28T12:46:26","slug":"eisai-seeks-approval-for-subcutaneous-leqembi-in-japan","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-seeks-approval-for-subcutaneous-leqembi-in-japan\/","title":{"rendered":"LEQEMBI\u76ae\u4e0b\u6ce8\u88fd\u5264\u306e\u65e5\u672c\u306b\u304a\u3051\u308b\u88fd\u9020\u8ca9\u58f2\u627f\u8a8d\u7533\u8acb\u306b\u3064\u3044\u3066"},"content":{"rendered":"

Eisai<\/a> \u3068\u305d\u306e\u30b0\u30ed\u30fc\u30d0\u30eb\u30fb\u30d1\u30fc\u30c8\u30ca\u30fc Biogen<\/a> have filed a new drug application with Japan’s Pharmaceuticals and Medical Devices Agency seeking approval of a subcutaneous version, SC‑AI, of its anti‑amyloid LEQEMBI for the treatment of early Alzheimer’s disease. If approved, this version would permit patients to receive injections at home from the outset-a major shift from the existing intravenous regimen.<\/p>

Data from the Phase 3 “Clarity AD” open-label extension supports the application. Weekly subcutaneous dosing of 500 mg, using two 250 mg injections, provides similar levels and results as IV dosing. It has a strong safety profile. Less than 2% of patients have reactions to systemic infusions.<\/p>

If approved, LEQEMBI will change Alzheimer’s treatment in Japan. It will be the first anti-amyloid therapy that patients can take at home from the beginning. This will greatly enhance the experience for patients and caregivers.<\/p>

\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a Kinko’s and Veeva Japan enter into partnership agreement<\/a><\/h4>

\u76ae\u4e0b\u6295\u4e0e\u3068\u3044\u3046\u9078\u629e\u80a2\u304c\u60a3\u8005\u3068\u533b\u7642\u306b\u3082\u305f\u3089\u3059\u3082\u306e<\/strong><\/h4>

\u76ae\u4e0bLEQEMBI\u306f\u3001\u6a19\u6e96\u7684\u306a\u9759\u8108\u5185\u6295\u4e0e\u6cd5\u3088\u308a\u3082\u91cd\u8981\u306a\u5229\u70b9\u304c\u3042\u308b\u304b\u3082\u3057\u308c\u307e\u305b\u3093\uff1a<\/p>

\u5229\u4fbf\u6027\u3068\u5feb\u9069\u6027<\/strong>: Patients can give themselves the injection at home. They don’t need to visit the hospital every two weeks.<\/p>

\u4f7f\u7528\u3059\u308b\u533b\u7642\u8cc7\u6e90\u306e\u6e1b\u5c11<\/strong>: SC‑AI simplifies therapy. It eliminates infusion prep, cuts down on nurse supervision, and streamlines hospital procedures.<\/p>

\u30a2\u30af\u30bb\u30b9\u306e\u6539\u5584<\/strong>:\u5728\u5b85\u7ba1\u7406\u306f\u3001\u79fb\u52d5\u306b\u554f\u984c\u304c\u3042\u308b\u60a3\u8005\u3055\u3093\u3084\u3001\u8f38\u6db2\u30af\u30ea\u30cb\u30c3\u30af\u3078\u306e\u30a2\u30af\u30bb\u30b9\u306b\u554f\u984c\u304c\u3042\u308b\u60a3\u8005\u3055\u3093\u306a\u3069\u3001\u3088\u308a\u591a\u304f\u306e\u60a3\u8005\u3055\u3093\u304c\u5229\u7528\u3067\u304d\u308b\u3088\u3046\u306b\u306a\u308a\u307e\u3059\u3002.<\/p>

Experts argue that this would reduce barriers to Alzheimer’s care in Japan-a fact that, given the demographic context, is particularly important.<\/p>

\u88fd\u85ac\u696d\u754c\u306b\u3068\u3069\u307e\u3089\u306a\u3044\u5e83\u7bc4\u306a\u5f71\u97ff\uff1a\u65e5\u672c\u306b\u304a\u3051\u308b\u6280\u8853\u3001\u30c7\u30fc\u30bf\u3001\u30d8\u30eb\u30b9\u30b1\u30a2\u30b5\u30fc\u30d3\u30b9\u306e\u610f\u5473\u3059\u308b\u3082\u306e<\/strong><\/h4>

The announcement highlights pharmaceutical development. It could also affect Japan’s tech industry, data infrastructure, and healthcare services:<\/p>

\u30c7\u30b8\u30bf\u30eb\u30d8\u30eb\u30b9\uff06\u30ea\u30e2\u30fc\u30c8\u30b1\u30a2\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u3078\u306e\u523a\u6fc0 <\/strong><\/p>

Home-injectable Alzheimer’s treatments are on the rise. This will boost the need for digital health tools. This covers remote monitoring systems, telemedicine platforms, and care management apps. Health-tech companies will discover new growth opportunities. This is especially true in elder care, remote monitoring, and patient data management.<\/p>

Data & AI-driven Alzheimer’s Care <\/strong><\/p>

\u81ea\u5b85\u3084\u8a3a\u7642\u6240\u3067\u306e\u6cbb\u7642\u304c\u5897\u3048\u3066\u3044\u307e\u3059\u3002\u305d\u306e\u305f\u3081\u3001\u30c7\u30fc\u30bf\u3092\u53ce\u96c6\u3001\u7ba1\u7406\u3001\u5206\u6790\u3059\u308b\u305f\u3081\u306e\u3088\u308a\u826f\u3044\u65b9\u6cd5\u304c\u5fc5\u8981\u3067\u3059\u3002\u3053\u306e\u30c7\u30fc\u30bf\u306f\u3001\u60a3\u8005\u304c\u6cbb\u7642\u8a08\u753b\u306b\u3069\u308c\u3060\u3051\u5f93\u3063\u3066\u3044\u308b\u304b\u3092\u8ffd\u8de1\u3059\u308b\u3082\u306e\u3067\u3059\u3002\u307e\u305f\u3001\u526f\u4f5c\u7528\u306e\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u3082\u884c\u3044\u307e\u3059\u3002\u3053\u3053\u3067\u306f\u60a3\u8005\u304b\u3089\u306e\u30d5\u30a3\u30fc\u30c9\u30d0\u30c3\u30af\u304c\u9375\u3068\u306a\u308b\u3067\u3057\u3087\u3046\u3002AI\u30d9\u30fc\u30b9\u306e\u533b\u7642\u30c7\u30fc\u30bf\u30fb\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3001\u96fb\u5b50\u30ab\u30eb\u30c6\u30fb\u30d7\u30ed\u30d0\u30a4\u30c0\u3001AI\u8a3a\u65ad\u30c4\u30fc\u30eb\u306f\u3001\u304a\u305d\u3089\u304f\u5927\u304d\u304f\u6210\u9577\u3059\u308b\u3067\u3057\u3087\u3046\u3002.<\/p>

\u30a4\u30f3\u30d5\u30e9\u3068\u4f9b\u7d66<\/strong>‑Chain Impacts<\/strong><\/p>

SC\u30aa\u30fc\u30c8\u30a4\u30f3\u30b8\u30a7\u30af\u30bf\u30fc\u3078\u306e\u30b7\u30d5\u30c8\u306f\u3001\u75c5\u9662\u5916\u3067\u306e\u4fdd\u7ba1\u3001\u6d41\u901a\u3001\u6295\u4e0e\u304c\u53ef\u80fd\u306a\u305f\u3081\u3001\u533b\u7642\u7528\u54c1\u306e\u7ba1\u7406\u65b9\u6cd5\u3092\u5909\u3048\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u3001\u5728\u5b85\u6cbb\u7642\u304c\u4e00\u822c\u7684\u306b\u306a\u308b\u306b\u3064\u308c\u3066\u3001\u7269\u6d41\u3001\u30b3\u30fc\u30eb\u30c9\u30c1\u30a7\u30fc\u30f3\u7ba1\u7406\u3001\u533b\u7642\u6a5f\u5668\u88fd\u9020\u3001\u533b\u85ac\u54c1\u30b5\u30d7\u30e9\u30a4\u30c1\u30a7\u30fc\u30f3\u30bd\u30d5\u30c8\u30a6\u30a7\u30a2\u306b\u643a\u308f\u308b\u4f01\u696d\u306e\u9700\u8981\u304c\u9ad8\u307e\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002.<\/p>

\u9ad8\u9f62\u8005\u4ecb\u8b77\u30b5\u30fc\u30d3\u30b9\u3068\u30a4\u30f3\u30b7\u30e5\u30a2\u30c6\u30c3\u30af\u306b\u5f3e\u307f<\/strong><\/p>

Our country leads the world in Alzheimer’s care innovation due to its high graying population rates. Caring for patients at home may soon be common. This shift will increase the need for full home-care services, remote caregiver support, and specialized health insurance for long-term neurological care. Insurtech firms and caregiving tech providers are ready to tap into this expanding market.<\/p>

\u30af\u30ed\u30b9<\/strong>‑Industry Collaboration Becomes Critical<\/strong><\/p>

Realizing these benefits will take collaboration among healthcare providers, technology companies, data platform vendors, regulatory bodies, and insurers. The LEQEMBI SC push may accelerate such cross-industry collaboration in Japan and help drive a more integrated “healthcare + technology” ecosystem.<\/p>

\u8ab2\u984c\u3068\u8003\u5bdf<\/strong><\/h4>

Regulatory review risks: Approval isn’t guaranteed. The PMDA will look at safety, efficacy, and how well SC administration works in real life.<\/p>

\u30a2\u30c9\u30d2\u30a2\u30e9\u30f3\u30b9\u3068\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0<\/strong>:\u5728\u5b85\u6295\u4e0e\u306f\u3001\u60a3\u8005\u3084\u4ecb\u8b77\u8005\u306b\u8cac\u4efb\u3092\u8ca0\u308f\u305b\u307e\u3059\u3002\u30a2\u30c9\u30d2\u30a2\u30e9\u30f3\u30b9\u3092\u52a9\u3051\u3001\u526f\u4f5c\u7528\u3092\u7ba1\u7406\u3059\u308b\u30b5\u30dd\u30fc\u30c8\u30b7\u30b9\u30c6\u30e0\u304c\u5fc5\u8981\u306b\u306a\u308b\u304b\u3082\u3057\u308c\u307e\u305b\u3093\u3002.<\/p>

\u30c7\u30fc\u30bf\u306e\u30d7\u30e9\u30a4\u30d0\u30b7\u30fc\u3068\u30bb\u30ad\u30e5\u30ea\u30c6\u30a3<\/strong>:\u5728\u5b85\u533b\u7642\u304c\u62e1\u5927\u3059\u308b\u4e2d\u3001\u60a3\u8005\u30c7\u30fc\u30bf\u306e\u5b89\u5168\u306a\u53d6\u308a\u6271\u3044\u306f\u4e0d\u53ef\u6b20\u3067\u3059\u3002\u7279\u306b\u3001\u30c7\u30b8\u30bf\u30eb\u30d8\u30eb\u30b9\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3084\u9060\u9694\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u306e\u53f0\u982d\u304c\u9855\u8457\u3067\u3059\u3002.<\/p>

\u30a4\u30f3\u30d5\u30e9\u3068\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306b\u306f\u3001\u533b\u7642\u6a5f\u5668\u306e\u30b5\u30d7\u30e9\u30a4\u30c1\u30a7\u30fc\u30f3\u3001\u5728\u5b85\u30b1\u30a2\u306e\u30ed\u30b8\u30b9\u30c6\u30a3\u30af\u30b9\u3001\u4ecb\u8b77\u8005\u306e\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u3001\u533b\u7642\u5ec3\u68c4\u7269\u306e\u7ba1\u7406\u306a\u3069\u304c\u542b\u307e\u308c\u307e\u3059\u3002.<\/p>

\u8ee2\u6a5f\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\u7406\u7531<\/strong><\/h4>

Japan can boost access to Alzheimer’s treatment by approving the SC-AI version of LEQEMBI. This breakthrough makes home care easier. It cuts down on burdens for patients and caregivers. Self-administration at home reduces stress, improves quality of life, and makes long-term treatment easier. This innovation helps businesses integrate healthcare and technology. It combines medicine with digital tools in Japan’s aging society.<\/p>

\u305d\u306e\u305f\u3081\u3001\u3053\u306e\u958b\u767a\u306f\u4e00\u822c\u7684\u306a\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u306e\u89e6\u5a92\u3068\u3057\u3066\u6a5f\u80fd\u3057\u3001\u7d50\u679c\u3068\u3057\u3066\u30c7\u30b8\u30bf\u30eb\u30d8\u30eb\u30b9\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3001\u9060\u9694\u30b1\u30a2\u3001AI\u306b\u3088\u308b\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u3001\u652f\u63f4\u30a4\u30f3\u30d5\u30e9\u306e\u6210\u9577\u3092\u4fc3\u9032\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002.<\/p>","protected":false},"excerpt":{"rendered":"

Eisai and its global partner Biogen have filed a new drug application with Japan’s Pharmaceuticals and Medical Devices Agency seeking approval of a subcutaneous version, SC‑AI, of its anti‑amyloid LEQEMBI for the treatment of early Alzheimer’s disease. If approved, this version would permit patients to receive injections at home from the outset-a major shift from the existing intravenous regimen.Data from the Phase 3 “Clarity AD” open-label extension supports the application. Weekly subcutaneous dosing of 500 mg, using two 250 mg injections, provides similar levels and results as IV dosing. It has a strong safety profile. Less than 2% of patients have reactions to systemic infusions.If approved, LEQEMBI will change Alzheimer’s […]<\/p>\n","protected":false},"author":7,"featured_media":24740,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[89,8098,182],"tags":[872,7394,1715,7393,424],"ppma_author":[572],"class_list":["post-24714","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health-tech","category-news-articles","category-pharma","tag-alzheimer-disease","tag-biogen","tag-eisai","tag-leqembi","tag-pharma"],"yoast_head":"\nEisai Pursues Approval of LEQEMBI Shot for Alzheimer\u2019s<\/title>\n<meta name=\"description\" content=\"Eisai and Biogen seek Japan approval for subcutaneous LEQEMBI, allowing at-home injections for early Alzheimer\u2019s treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-seeks-approval-for-subcutaneous-leqembi-in-japan\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai Pursues Approval of LEQEMBI Shot for Alzheimer\u2019s\" \/>\n<meta property=\"og:description\" content=\"Eisai and Biogen seek Japan approval for subcutaneous LEQEMBI, allowing at-home injections for early Alzheimer\u2019s treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-seeks-approval-for-subcutaneous-leqembi-in-japan\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-28T11:31:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-28T12:46:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/11\/2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"ITBT StaffWriter\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ITBT StaffWriter\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u578b\u8a8d\u77e5\u75c7\u6cbb\u7642\u85acLEQEMBI\u6ce8\u5c04\u5264\u306e\u627f\u8a8d\u53d6\u5f97\u306b\u3064\u3044\u3066","description":"\u30a8\u30fc\u30b6\u30a4\u3068\u30d0\u30a4\u30aa\u30b8\u30a7\u30f3\u793e\u3001LEQEMBI\u76ae\u4e0b\u6ce8\u88fd\u5264\u306e\u65e5\u672c\u3067\u306e\u627f\u8a8d\u7533\u8acb \u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u578b\u8a8d\u77e5\u75c7\u306e\u65e9\u671f\u6cbb\u7642\u306b\u5728\u5b85\u6ce8\u5c04\u304c\u53ef\u80fd\u306b.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-seeks-approval-for-subcutaneous-leqembi-in-japan\/","og_locale":"ja_JP","og_type":"article","og_title":"Eisai Pursues Approval of LEQEMBI Shot for Alzheimer\u2019s","og_description":"Eisai and Biogen seek Japan approval for subcutaneous LEQEMBI, allowing at-home injections for early Alzheimer\u2019s treatment.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-seeks-approval-for-subcutaneous-leqembi-in-japan\/","og_site_name":"itbusinesstoday","article_published_time":"2025-11-28T11:31:06+00:00","article_modified_time":"2025-11-28T12:46:26+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/11\/2.webp","type":"image\/webp"}],"author":"ITBT StaffWriter","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"ITBT StaffWriter","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"4\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-approval-for-subcutaneous-leqembi-in-japan\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-approval-for-subcutaneous-leqembi-in-japan\/"},"author":{"name":"ITBT StaffWriter","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15"},"headline":"Eisai Seeks Approval for Subcutaneous LEQEMBI in Japan","datePublished":"2025-11-28T11:31:06+00:00","dateModified":"2025-11-28T12:46:26+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-approval-for-subcutaneous-leqembi-in-japan\/"},"wordCount":788,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-approval-for-subcutaneous-leqembi-in-japan\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/11\/2.webp","keywords":["Alzheimer disease","Biogen","Eisai","LEQEMBI","Pharma"],"articleSection":["Health Tech","News Articles","Pharma"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-approval-for-subcutaneous-leqembi-in-japan\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-approval-for-subcutaneous-leqembi-in-japan\/","name":"\u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u578b\u8a8d\u77e5\u75c7\u6cbb\u7642\u85acLEQEMBI\u6ce8\u5c04\u5264\u306e\u627f\u8a8d\u53d6\u5f97\u306b\u3064\u3044\u3066","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-approval-for-subcutaneous-leqembi-in-japan\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-approval-for-subcutaneous-leqembi-in-japan\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/11\/2.webp","datePublished":"2025-11-28T11:31:06+00:00","dateModified":"2025-11-28T12:46:26+00:00","description":"\u30a8\u30fc\u30b6\u30a4\u3068\u30d0\u30a4\u30aa\u30b8\u30a7\u30f3\u793e\u3001LEQEMBI\u76ae\u4e0b\u6ce8\u88fd\u5264\u306e\u65e5\u672c\u3067\u306e\u627f\u8a8d\u7533\u8acb \u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u578b\u8a8d\u77e5\u75c7\u306e\u65e9\u671f\u6cbb\u7642\u306b\u5728\u5b85\u6ce8\u5c04\u304c\u53ef\u80fd\u306b.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-approval-for-subcutaneous-leqembi-in-japan\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-approval-for-subcutaneous-leqembi-in-japan\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-approval-for-subcutaneous-leqembi-in-japan\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/11\/2.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/11\/2.webp","width":1200,"height":800,"caption":"eisai"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-seeks-approval-for-subcutaneous-leqembi-in-japan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Eisai Seeks Approval for Subcutaneous LEQEMBI in Japan"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15","name":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png90b3cb23d1d9c08733d969d29ea2d30d","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","caption":"ITBT StaffWriter"},"description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002","sameAs":["https:\/\/itbusinesstoday.com\/"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/itbt-staffwriter\/"}]}},"authors":[{"term_id":572,"user_id":7,"is_guest":0,"slug":"itbt-staffwriter","display_name":"ITBT StaffWriter","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png"},"author_category":"","first_name":"ITBT","last_name":"StaffWriter","user_url":"https:\/\/itbusinesstoday.com\/","job_title":"","description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002"}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/24714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=24714"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/24714\/revisions"}],"predecessor-version":[{"id":24716,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/24714\/revisions\/24716"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/24740"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=24714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=24714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=24714"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=24714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}